| Latest Forum Topics / Boustead Last:1.79 -- |
 Post Reply
|
|
Boustead on the move now
|
|||||||||||||
|
tangsookiam1947
Master |
15-Aug-2026 07:56
|
||||||||||||
|
x 0
x 0 Alert Admin |
We have been looking more closely at Boustead Singapore, and at around S$1.90 per share, the valuation looks increasingly interesting. The investment case can be simplified into one question: After accounting for Boustead' s cash and stake in UI Boustead REIT, how much are investors actually paying for the rest of the Group? About S$1.00 Per Share Is Already Backed by Cash and UI Boustead REIT Boustead has a very strong balance sheet, with its net cash position representing roughly S$0.65&ndash S$0.70 per share. On top of this, Boustead retains an economic interest in UI Boustead REIT, which provides further listed asset backing. Taken together, we estimate that cash plus the REIT interest account for roughly S$1.00 per Boustead share. At a Boustead share price of approximately S$1.90, this means investors are effectively paying only around: S$1.90 &ndash S$1.00 = S$0.90 per share for the rest of Boustead. And that remaining 90 cents buys quite a lot. Geospatial Is Potentially Worth more than 90 Cents by Itself Boustead Geospatial is arguably the Group' s crown jewel. The business is a major distributor of Esri' s geographic information system technology across Australia and parts of Asia, with recurring software, maintenance and professional-service revenues. The division generates around S$50 million of annual operating profit. If we were to place even a relatively conservative valuation on a profitable, asset-light technology distribution and services business of this quality, Geospatial alone could potentially account for a substantial portion of the implied value currently assigned to all of Boustead' s operating businesses. Yet the 90 cents also buys us:
The S$7.6 Billion Real-Estate Pipeline Could Be the Bigger Long-Term Story The market may also be underestimating what the creation of UI Boustead REIT means for Boustead' s real-estate business. The UI Boustead REIT prospectus identifies an acquisition pipeline of approximately US$5.9 billion, or S$7.6 billion, comprising completed properties as well as projects under development, secured land and projects under exclusive negotiation. The pipeline covers approximately 19.6 million sq ft. More importantly, UI Boustead REIT has been positioned as the Sponsor' s capital-recycling vehicle for Pan-Asian stabilised industrial and logistics assets. This potentially creates a repeatable model: Develop &rarr Lease &rarr Stabilise &rarr Sell to REIT &rarr Recycle Capital &rarr Develop Again Boustead can potentially earn at several stages of this cycle &mdash development profits, investment returns and recurring income associated with the enlarged real-estate platform. This is very different from valuing Boustead Projects simply as a conventional construction company. And the Pipeline Is Still Expanding Boustead has continued securing major projects. In FY2026, the Group secured approximately S$360 million of new engineering contracts and variation orders. Remarkably, in just the first two months of FY2027, Boustead had already secured another S$461 million, exceeding the entire FY2026 amount. This included Boustead Projects' largest contract to date, worth more than S$400 million. There is also the new aerospace development at 11 Seletar Aerospace Link. These developments matter because today' s projects can potentially become tomorrow' s stabilised investment properties and, where suitable, future candidates for capital recycling. COMO Metropolitan Singapore Is Another Potentially Underappreciated Asset We should also not forget COMO Metropolitan Singapore. Boustead acquired the underlying property during the COVID-era downturn, when Singapore hospitality and commercial property valuations were under significant pressure. Today, the operating environment is very different. If the property is eventually monetised at an attractive valuation, it could represent another source of value that is not obvious when investors look only at Boustead' s annual recurring earnings. The Balance Sheet Gives Boustead Optionality Perhaps the most important part of the thesis is that Boustead does not need everything to go right. Its substantial cash position gives management considerable flexibility. The cash can potentially be used for acquisitions, new developments, investments alongside its real-estate partners, dividends, share buybacks or simply held until attractive opportunities appear. In that sense, the cash is not merely sitting on the balance sheet. It represents future earning power that has yet to be deployed. So What Are We Really Paying S$1.90 For? The simplest way to look at Boustead may therefore be: S$1.90 share price less approximately S$1.00 (net cash + UI Boustead REIT interest) leaves approximately S$0.90 for everything else. For that 90 cents, investors effectively gain exposure to a Geospatial business generating around S$50 million of operating profit, Boustead Projects (EPC + non-divested assets e.g. Vietnam platform), Energy Engineering, Healthcare, COMO Metropolitan Singapore and Boustead' s participation in a real-estate platform with an identified S$7.6 billion acquisition pipeline. That appears to provide a considerable margin of safety if the underlying businesses continue performing. The market may currently be concentrating on the decline in Boustead' s normalised FY2026 earnings following an exceptionally strong previous year. Boustead itself reported FY2026 attributable net profit of S$232.6 million, largely boosted by gains from the sale of 21 Singapore properties to UI Boustead REIT, while normalised profit was lower year-on-year. But that may be precisely the point. The market is looking at what Boustead earned yesterday. The more interesting question is what its collection of businesses, cash and assets can earn &mdash or be worth &mdash tomorrow. At around S$1.90, that gap between price and underlying value is what makes Boustead worth watching closely. Disclaimer This post is for informational and educational purposes only. It does not constitute financial advice, investment recommendation, or an offer to buy or sell any security. Investors should conduct their own due diligence, consider their personal financial circumstances and risk tolerance, and consult a licensed financial adviser where appropriate. Past performance is not indicative of future results, and investing in equities carries risk of capital loss. |
||||||||||||
| Useful To Me Not Useful To Me | |||||||||||||
|
HVRRVH
Elite |
13-Aug-2026 16:16
|
||||||||||||
|
x 0
x 0 Alert Admin |
scipt price $1.75 and shall subscribe partially for it to round up holding to whole sum. likely to see improvement of income for Boustead and hence, higher dividends going forward. | ||||||||||||
| Useful To Me Not Useful To Me | |||||||||||||
|
|
|||||||||||||
|
tangsookiam1947
Master |
07-Aug-2026 14:45
|
||||||||||||
|
x 0
x 0 Alert Admin |
At S$1.90, Boustead May Be One of SGX' s Cheapest Quality Companies
Benjamin Graham famously said, " In the short run, the market is a voting machine, but in the long run, it is a weighing machine."
Today, Boustead Singapore looks like one of those rare situations where the market is focusing on recent earnings while overlooking what the company actually owns.
At around S$1.90 per share, the valuation appears increasingly difficult to justify.
S$1.00 of Every Share Is Already Backed by Cash and Listed Investments
The maths is remarkably simple.
Boustead currently has:
Net cash of roughly S$0.65&ndash 0.70 per share
Its 16.9% stake in UI Boustead REIT, worth approximately S$0.30&ndash 0.35 per share at current market prices
Together, these account for about S$1.00 per share.
In other words, when investors buy Boustead at S$1.90, they are effectively paying only 90 cents for the rest of the Group.
That is where the opportunity begins.
Geospatial Alone Generates Around S$50 Million of Operating Profit
Boustead Geospatial is arguably the crown jewel of the Group.
As one of the world' s largest distributors of Esri GIS software across Australia and Southeast Asia, it enjoys a high-quality business model built on recurring software licences, maintenance contracts and professional services.
In FY2026, the Geospatial division generated approximately S$50 million of operating profit.
Yet after deducting Boustead' s net cash and listed REIT investment, the market is effectively valuing not only this highly profitable Geospatial business, but also every other operating division, at just 90 cents per share.
That simply does not look expensive.
A S$7.6 Billion Acquisition Pipeline That Many Investors Overlook
Perhaps the market' s biggest blind spot is Boustead' s long-term real estate platform.
According to the UI Boustead REIT Prospectus, the Sponsor has an acquisition pipeline of approximately US$5.9 billion (around S$7.6 billion)across Asia. This includes completed income-producing assets, projects under development, secured land and projects under exclusive negotiation. (SGX Links)
More importantly, bothBoustead ProjectsandUnified Industrialhave grantedUI Boustead REITaRight of First Refusal (ROFR)over suitable future industrial and logistics assets. The Sponsor has also stated thatUI Boustead REIT will serve as its sole capital recycling vehicle for Pan-Asian stabilised industrial and logistics assets. (Boustead)
This creates a powerful long-term growth engine.
Rather than simply developing and selling properties, Boustead can:
Develop high-quality industrial assets.
Stabilise them with long-term tenants.
Inject them into UI Boustead REIT when conditions are attractive.
Recycle the capital into the next generation of developments.
It is a business model that can generate development profits, recurring management fees, asset management income and long-term investment returns simultaneously.
The Pipeline Continues to Grow
The pipeline is not static.
Recent announcements include:
11 Seletar Aerospace Link, a new aerospace facility being jointly developed in Singapore.
Boustead Projects' largest engineering contract to date, worthover S$400 million.
Continued expansion opportunities in Japan, including logistics developments that could eventually become suitable REIT assets once stabilised. (Boustead)
Each successful project increases the pool of potential assets that may eventually be monetised through the REIT platform.
Don' t Forget COMO Metropolitan Singapore
Another hidden asset is COMO Metropolitan Singapore.
The property was acquired during the COVID-19 downturn when hospitality assets were under significant pressure.
With Singapore' s hotel sector now enjoying record tourist arrivals, strong occupancy and higher room rates, this investment could prove to be another valuable long-term asset that is barely reflected in today' s share price.
A Fortress Balance Sheet
Boustead' s greatest competitive advantage remains its balance sheet.
Few SGX-listed companies possess such a strong net cash position.
This gives management tremendous flexibility to:
increase dividends,
undertake share buybacks,
acquire businesses during downturns,
invest alongside UI Boustead REIT,
and seize opportunities when competitors are constrained.
Cash is not just a defensive asset&mdash it is future earning power waiting for the right opportunity.
The Market May Simply Be Looking in the Rear-View Mirror
Investors today appear to be paying 90 cents for:
A Geospatial business generating around S$50 million of annual operating profit
Boustead Projects
Energy Engineering
Healthcare
COMO Metropolitan Singapore
Access to a S$7.6 billion sponsor pipeline through the UI Boustead REIT platform
An experienced management team with an exceptional long-term capital allocation record
That is an extraordinary collection of assets and businesses for just 90 cents per share after accounting for Boustead' s cash and listed REIT investment.
Markets do not remain inefficient forever.
If earnings recover, more assets are recycled through the REIT platform and the cash pile continues to grow, today' s valuation could one day be remembered as one of the most attractive entry points in Boustead' s history.
Sometimes the market prices a company based on yesterday' s earnings. Long-term investors, however, are rewarded for recognising tomorrow' s value.
Disclaimer
This post is for informational and educational purposes only. It does not constitute financial advice, investment recommendation, or an offer to buy or sell any security. Investors should conduct their own due diligence, consider their personal financial circumstances and risk tolerance, and consult a licensed financial adviser where appropriate. Past performance is not indicative of future results, and investing in equities carries risk of capital loss.
|
||||||||||||
| Useful To Me Not Useful To Me | |||||||||||||
|
tangsookiam1947
Master |
29-Jul-2026 20:52
|
||||||||||||
|
x 0
x 0 Alert Admin |
Will price recover strongly after the script determination period? === If OCBC' s forecasts of 26.3 cents EPS for FY27 and 37.9 cents for FY28 materialise, we think Boustead' s share price could comfortably break through S$3.00. At S$3.00, the stock would still be trading at only 7.9X FY28 earnings, which remains attractive for a company with multiple quality businesses spanning Geospatial, Engineering, Real Estate and Healthcare. OCBC also projects Boustead' s cash balance to rise to S$535 million by FY28, equivalent to more than S$1.00 of cash per share, giving the company tremendous flexibility to increase dividends, undertake share buybacks or pursue value-accretive acquisitions.
Interestingly, OCBC' s fair value of S$2.67 is not an outlier. Another respected research house, Lim & Tan Securities, has also initiated coverage with a target price of S$2.70, suggesting that independent analysts are arriving at broadly similar valuations based on today' s information. It is also worth remembering that sell-side analysts are generally conservative by nature. Their models typically incorporate only earnings that are reasonably visible, while future contract wins, successful acquisitions, additional REIT asset injections or stronger-than-expected growth are usually recognised only after they become more certain. If Boustead continues to execute well, there is scope for actual earnings to exceed current forecasts.
Perhaps the most exciting aspect is that Boustead is evolving into a long-term capital compounder rather than just an engineering company. As profits increase, the already substantial cash pile continues to grow, providing management with even greater firepower to create shareholder value. If FY28 earnings prove to be sustainable rather than a one-off peak, the market may eventually be willing to assign a higher valuation multiple. In that scenario, S$3.00 could simply be the next milestone, rather than the destination, particularly for a company with a fortress balance sheet, multiple growth engines and a management team that has consistently demonstrated disciplined capital allocation.
|
||||||||||||
| Useful To Me Not Useful To Me | |||||||||||||
|
tangsookiam1947
Master |
15-Jul-2026 20:39
|
||||||||||||
|
x 0
x 0 Alert Admin |
Boustead: Is S$3.00 Just the Beginning? https://www.moomoo.com/community/feed/116923693268998?share_code=0EpV0x
|
||||||||||||
| Useful To Me Not Useful To Me | |||||||||||||
|
|
|||||||||||||
|
HVRRVH
Elite |
15-Jul-2026 12:00
|
||||||||||||
|
x 0
x 0 Alert Admin |
scrip price will make known in about a month time. currently share price seems to stable and hold strong at $2.1 level with occasional down drift toward $2 but always bounce back up. likely for scrip to price slightly below $2 if discount is only 5%. hopefully company can give bigger discount if not personally I may give the scrip a miss this time.
|
||||||||||||
| Useful To Me Not Useful To Me | |||||||||||||
|
tangsookiam1947
Master |
05-Jul-2026 15:38
|
||||||||||||
|
x 0
x 0 Alert Admin |
Investment viewThe market tends to focus on Boustead' s reported EPS, which can fluctuate significantly depending on whether there are major asset sales or REIT-related gains. A better way to value the company is to separate the recurring operating businesses from its capital recycling strategy. On a recurring basis, the group appears capable of generating around 23 cents of EPS annually. This is supported by three high-quality earnings engines: Geospatial (around 10 cents), recurring income from its large cash balance and UIB REIT stake (around 7 cents), and its engineering businesses (around 6 cents combined). The additional upside comes from Boustead' s unique business model. Unlike a traditional EPC contractor, it develops industrial properties, monetises them through UI Boustead REIT, and then redeploys the capital into the next development cycle. If the sponsor continues injecting one or two assets into the REIT each year, these divestments could reasonably contribute another 3&ndash 5 cents per share annually, lifting sustainable earnings towards 26&ndash 28 cents per share. Over time, if the REIT grows substantially and healthcare begins contributing meaningfully, there is further upside beyond this base-case framework. https://www.moomoo.com/community/feed/116866218917894?share_code=0DHLDj
|
||||||||||||
| Useful To Me Not Useful To Me | |||||||||||||
|
tangsookiam1947
Master |
05-Jul-2026 11:17
|
||||||||||||
|
x 0
x 0 Alert Admin |
Boustead still have a lot of assets to be divested .....no wonder the forecast EPS for 2027 and 2028 so high? https://www.moomoo.com/community/feed/116696084054022?share_code=0DHbmv The more immediate one is the 36 Tuas Road - $220 mil to be divested to UIB reits.. after that, the vietnam platform (at least $250mil), etc
|
||||||||||||
| Useful To Me Not Useful To Me | |||||||||||||
|
|
|||||||||||||
|
HVRRVH
Elite |
05-Jul-2026 09:49
|
||||||||||||
|
x 0
x 0 Alert Admin |
Thanks for highlighting the report/est EPS again and indeed, 26.3 cents and 37.9 cents are forecasted for FY27 and 28 respecivelty. Now with the expansion of healthcare business via the 60% acquistion of UroMedTech probably $3 will come to fruition in due time. Let' s see.
|
||||||||||||
| Useful To Me Not Useful To Me | |||||||||||||
|
tangsookiam1947
Master |
04-Jul-2026 22:57
|
||||||||||||
|
x 0
x 0 Alert Admin |
thought usually analysts are very conservative!!!
|
||||||||||||
| Useful To Me Not Useful To Me | |||||||||||||
|
tangsookiam1947
Master |
04-Jul-2026 21:25
|
||||||||||||
|
x 0
x 0 Alert Admin |
yes, it was cited in the OCBC report...
https://www.moomoo.com/community/feed/116861928013830?share_code=0DFPZ9
|
||||||||||||
| Useful To Me Not Useful To Me | |||||||||||||
|
HVRRVH
Elite |
04-Jul-2026 16:25
|
||||||||||||
|
x 0
x 0 Alert Admin |
I didn?t see the est 27?s and 28?s eps from the attached link. If stabilised eps is indeed 37.9 cents then easily the share price will breach $3. A 16 cents dividend will yield 5.3% if share price is $3. We shall see.
|
||||||||||||
| Useful To Me Not Useful To Me | |||||||||||||
|
|
|||||||||||||
|
tangsookiam1947
Master |
04-Jul-2026 14:15
|
||||||||||||
|
x 0
x 0 Alert Admin |
https://www.moomoo.com/community/feed/116860229779462?share_code=0DF8EvUIB REIT: A Long-Term Value Engine for Boustead
Key takeaway: Boustead is not just a developer&mdash it is also a long-term owner. Every asset sold into UIB REIT creates an immediate development profit, while the retained 16.9% stake compounds in value as the REIT grows, generating both capital appreciation and recurring distributions for decades.
|
||||||||||||
| Useful To Me Not Useful To Me | |||||||||||||
|
Joelton
Supreme |
04-Jul-2026 14:12
|
||||||||||||
|
x 0
x 0 Alert Admin |
Boustead healthcare unit acquires majority stake in medtech company via S$6 million equity injection [SINGAPORE] Boustead Singapore : F9D +2.45% unit Boustead Medical Care Holdings (BMCH) has acquired a 60 per cent stake in a urology robotics company through a S$6 million equity injection, the engineering and technology group said on Friday (Jul 3). BMCH, which falls under Boustead&rsquo s healthcare division, focuses on rehabilitation robotics, digital healthcare and medical innovation. Singapore-based UroMedTech is known for pioneering robotic solutions for prostate cancer diagnosis through its UroMaster system. Its R& D road map includes integrating focal therapy treatment, a minimally invasive method to target tumours, within UroMaster. Boustead said the investment will expand its healthcare technology portfolio into &ldquo the rapidly growing precision urology and oncology field, (while positioning) the group to capitalise on emerging trends in artificial intelligence-driven technology&rdquo . It added: &ldquo Through the acquisition, BMCH intends to accelerate the commercialisation of UroMaster, support the development of these next-generation capabilities, and expand UroMedTech&rsquo s international presence by leveraging its regional distribution network, which includes public and private clinics and hospitals.&rdquo After the transaction is completed, UroMedTech will continue to operate under its existing brand and also work closely with BMCH to expand R& D, strengthen clinical partnerships and pursue regulatory approvals in key international markets. The acquisition is part of BMCH&rsquo s strategy to &ldquo secure long-term growth prospects through scalable, high-margin medical technology (platforms) with recurring revenue opportunities from consumables, software subscriptions and clinical services&rdquo , Boustead said. The deal is not expected to have a material impact on the group&rsquo s profitability, earnings per share and tangible net asset value per share in the financial year ending Mar 31, 2027. Boustead shares closed at S$2.09 on Friday, up S$0.05 or 2.5 per cent, before the announcement. |
||||||||||||
| Useful To Me Not Useful To Me | |||||||||||||
|
tangsookiam1947
Master |
04-Jul-2026 12:34
|
||||||||||||
|
x 0
x 0 Alert Admin |
Boustead Singapore: Look Beyond The Noise
Although OCBC forecasts FY27 EPS to decline sharply from 46.6 cents to 26.3 cents, this should not be interpreted as a deterioration in Boustead' s underlying business. FY26 earnings were significantly boosted by the successful listing of UI Boustead REIT, which generated a substantial one-off gain. Excluding this exceptional item, FY27 represents a normalization of earnings rather than a collapse in operating performance. Looking ahead, OCBC expects earnings to recover meaningfully in FY28, with EPS rising 44% to 37.9 cents. The recovery is expected to be driven primarily by Boustead' s S$840 million engineering order backlog, continued strength in its Real Estate Solutions business, and the resumption of steady growth in the Geospatial division after temporary accounting-related headwinds. While margins are expected to remain under some pressure due to higher construction and input costs, revenue is forecast to grow strongly from S$747 million in FY27 to S$933 million in FY28. Importantly, even after normalising earnings, Boustead is projected to generate 26.3 cents of EPS in FY27 and 37.9 cents in FY28, implying attractive forward valuations relative to its share price. Combined with a forecast dividend of 10.5 cents in FY27 rising to 15.2 cents in FY28, and supported by a strong net cash position and visible project pipeline, OCBC maintains its BUY rating with a fair value of S$2.67, suggesting the market may be overly focused on the one-off earnings decline instead of the company' s longer-term earnings trajectory.
|
||||||||||||
| Useful To Me Not Useful To Me | |||||||||||||
|
Nippon72
Veteran |
04-Jul-2026 11:06
Yells: "Dude, is ALWAYS Time in the market than Timing the market! " |
||||||||||||
|
x 0
x 0 Alert Admin |
Mathematically is as such, question is what level does market accord it? So my litmus test is whether its divvy can reward or compensate me while waiting for Boustead to brew. I always try to use either SRS or CPFIS for such counters the divvy sure beats its rate, forces me to think long term since money parked aside till 63/55yo, ride out all the noises & temptation. Vested. My real litmus test is at 63 will I sell it? Meanwhile enjoying the brew. |
||||||||||||
| Useful To Me Not Useful To Me | |||||||||||||
|
HVRRVH
Elite |
04-Jul-2026 10:35
|
||||||||||||
|
x 0
x 0 Alert Admin |
It is quite obvious the money invested came from the divestment of properties to UIB. A very smart and shrewd move. The new investment is still a related healthcare business so Boustead put money into something they already have knowledge of and even thought the amount is 6m, it constitutes 60% of the total shares. In the filing, CEO of UroMed said, among other things, they are seeking regulatory approval too in US so the potential is huge, especially if it grows big enough, it has the potential of crafting out and list in or 2nd list in Nasdaq. So far market insiders seems positive and move the share price up by 2.45% with highest volume for the week. For a company with such long history, Boustead seems to have found another impetus for growing.
|
||||||||||||
| Useful To Me Not Useful To Me | |||||||||||||
|
tangsookiam1947
Master |
04-Jul-2026 09:33
|
||||||||||||
|
x 0
x 0 Alert Admin |
https://www.moomoo.com/community/feed/116858833600518?share_code=0DEFuo The acquisition of a 60% stake in UroMedTech has the potential to become a meaningful long-term value driver for Boustead, despite its relatively small upfront investment of S$6 million. Robotic-assisted urology is a rapidly expanding segment driven by ageing populations, increasing prostate cancer incidence, and demand for more precise, minimally invasive procedures. If UroMaster successfully secures regulatory approvals in key markets such as Europe and the United States, the addressable market could expand from a niche Singapore opportunity to a global medical technology business serving thousands of hospitals and specialist centres.
Beyond product sales, the business model could become highly scalable. Surgical robotics companies typically generate recurring revenue from disposable instruments, service contracts, software upgrades and maintenance, which often produce higher margins than the initial capital equipment sale. This creates a recurring revenue stream similar to the " razor-and-blade" model, where every installed system continues generating income throughout its operating life. As the installed base grows, earnings can compound much faster than hardware sales alone.
If UroMedTech executes successfully and achieves meaningful commercial traction, the value created could be several multiples of Boustead' s initial investment. Comparable listed surgical robotics companies often trade at enterprise values of several hundred million to several billion dollars once they demonstrate regulatory approval, clinical adoption and recurring revenues.
Even assuming a conservative future valuation of S$300&ndash 600 million for UroMedTech, Boustead' s 60% stake would be worth S$180&ndash 360 million, equivalent to approximately S$0.36&ndash 0.71 per Boustead share (based on approximately 505 million shares outstanding). Under a more optimistic scenario where UroMaster becomes a globally adopted platform, the upside could be substantially higher, making this one of the group' s most significant long-term growth options.
|
||||||||||||
| Useful To Me Not Useful To Me | |||||||||||||
|
tangsookiam1947
Master |
22-Jun-2026 18:32
|
||||||||||||
|
x 0
x 0 Alert Admin |
Analysts Offer Insights on Industrial Goods Companies: Compagnie de Saint Gobain (SGO) and Boustead Singapore (BSTGF) - The Globe and Mail does anyone have the Lim and Tan report that recommended TP of $2.70 for Boustead? |
||||||||||||
| Useful To Me Not Useful To Me | |||||||||||||
|
tangsookiam1947
Master |
17-Jun-2026 23:03
|
||||||||||||
|
x 0
x 0 Alert Admin |
it should stabilize at above $2.50 .... give it a few months until year end...Sum of parts easily more than $3.50... https://www.moomoo.com/community/feed/116759809556486?share_code=0CntQR
|
||||||||||||
| Useful To Me Not Useful To Me | |||||||||||||
